

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response...	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * KOSKI FAMILY LP		2. Issuer Name and Ticker or Trading Symbol ORAGENICS INC [OGEN]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)	
(Last) (First) (Middle) 3525 TURTLE CREEK BOULEVARD, UNIT 19-B		3. Date of Earliest Transaction (Month/Day/Year) 11/08/2017			
(Street) DALLAS, TX 75219		4. If Amendment, Date Original Filed (Month/Day/Year)		6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person	
(City) (State) (Zip)		<b>Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned</b>			

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock							12,864,822	D (1) (2)		
Common Stock							1,572,523	D (3)		
Common Stock							1,087,878	D (4) (8)		
Common Stock							519,666	D (5)		
Common Stock							20,000	I (6)	By Koski Management, Inc.	
Common Stock							530,851	I (7)	By Trusts	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Series B Convertible Preferred Stock	\$ 0.25	11/08/2017		J		1,500,000	(8)	(8)	(8)	Common Stock	3,000,000	\$ 0	3,000,000	D	
Common Stock Warrant	\$ 0.31	11/08/2017		J		2,419,355	(9)		05/08/2018 11/08/2024	Common Stock	2,419,355	\$ 0.31	5,419,355	D	

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
KOSKI FAMILY LP 3525 TURTLE CREEK BOULEVARD, UNIT 19-B DALLAS, TX 75219		X		
KOSKI ROBERT C 7362 HAWKINS ROAD SARASOTA, FL 34241	X	X		
KOSKI THOMAS L. 4995 ASHLEY PARKWAY SARASOTA, FL 34241		X		
KOSKI CHRISTINE L 3525 TURTLE CREEK BOULDEVARD, UNIT 19-B DALLAS, TX 75219		X		
KOSKI BEVERLY 3525 TURTLE CREEK BOULDEVARD, UNIT 19-B DALLAS, TX 75219		X		

## Signatures

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Shares owned directly by Koski Family Limited Partnership ("KFLP"). Shares owned indirectly by the KFLP general partners: Koski Management, Inc. (solely owned by Beverly Koski), Christine L. Koski, Robert C. Koski and Thomas L. Koski, each of whom is a general partner of the partnership or the controlling person of a corporate general partner of the partnership.

(2) Each reporting person disclaims beneficial ownership of all indirectly owned securities in excess of such reporting person's pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner for purposes of Section 16 or any other purpose.

(3) Shares owned directly by Christine L. Koski.

(4) Shares owned directly by Robert C. Koski, a director of the Company.

(5) Shares owned directly by Thomas L. Koski.

(6) Shares owned indirectly by Beverly Koski (through Koski Management, Inc.).

(7) Shares owned by trusts of which Mr. Robert C. Koski is sole trustee. Such trusts are as follows: the Robert Clayton Koski Trust for the benefit of Anthony James Hunter (100,000 shares); the Robert Clayton Koski Trust for the benefit of Hunter Buchanan Koski (100,000 shares); the Robert Clayton Koski Trust for the benefit of Clayton Ward Bennett (100,000 shares); the Robert Clayton Koski Trust for the benefit of Robert Edward Koski (100,000 shares); and the Robert Clayton Koski Trust for the benefit of Elyse Margaux Koski (97,666 shares). Mr. Koski disclaims beneficial ownership of the shares held by the trusts except to the extent of any pecuniary interest.

(8) On November 8, 2017 the Company issued to the KFLP 1,500,000 shares of Series B Preferred Stock at a purchase price of \$0.50 per share which are convertible into 3,000,000 shares of the Company's Common Stock, based on a conversion ratio of one share of Series B Preferred Stock into two shares of common stock. The purchase price per share represented by the shares of common stock the Series B Preferred Stock is convertible into equates to \$0.25 per share. The Series B Convertible Preferred Stock will be convertible into shares of common stock commencing on the effective date of shareholder approval and has no expiration date.

(9) On November 8, 2017, the Company issued to the KFLP in the private placement a warrant to purchase 2,419,355 shares of Common Stock. The Warrant has a term of seven years from the date of issuance, are non-exercisable until 6 months after issuance, and have an exercise price of \$0.31 per share. The exercisability of the Warrant into shares of common stock is also subject to shareholder approval.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.